EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics provides shareholders with the following update on current trading and performance bonuses.
EKF Diagnostics announces that it has entered into a non-exclusive Preferred Partner Arrangement with Mount Sinai Innovation Partners.
EKF Diagnostics announces its unaudited interim results for the six months ended 30 June 2019.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its interim results for the six months ended 30 June 2019 on Tuesday 10 September 2019.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, provides the following trading update.
EKF Diagnostics Holdings plc (AIM: EKF) announces that 250,000 share options over ordinary shares of 1 penny each granted to a PDMR of the Company have been cancelled at the election of the option holder in return for the payment of a one-off cash sum.
Standard form for notification of major holdings.
EKF Diagnostics Holdings plc (AIM: EKF) announces that on 24 May 2019, the Company was notified by Adam Reynolds, Non-executive Director, that he has today sold 400,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares").
EKF Diagnostics Holdings notes the announcement by Renalytix AI plc, that on 26 April 2019 EKF Diagnostics plc acquired 100,074 ordinary RenalytixAI shares of £0.0025 each.
EKF Diagnostics confirms that the Annual Report and Accounts for the year ended 31 December 2018 and the Notice of the Annual General Meeting contained therein are available.